Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches

被引:155
|
作者
Gilbert, Ian H. [1 ]
机构
[1] Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Drug Discovery Unit, Dundee DD1 5EH, Scotland
基金
英国惠康基金;
关键词
PROTEIN N-MYRISTOYLTRANSFERASE; PTERIDINE REDUCTASE 1; CANDIDA-ALBICANS; MYRISTOYL-COA; PEPTIDOMIMETIC INHIBITORS; TRYPANOSOMA-BRUCEI; DIHYDROOROTATE DEHYDROGENASE; SELECTIVE INHIBITORS; CROSS-RESISTANCE; DIPEPTIDE AMIDES;
D O I
10.1021/jm400362b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug discovery for neglected tropical diseases is carried out using both target-based and phenotypic approaches. In this paper, target-based approaches are discussed, with a particular focus on human African trypanosomiasis. Target-based drug discovery can be successful, but careful selection of targets is required. There are still very few fully validated drug targets in neglected diseases, and there is a high attrition rate in target-based drug discovery for these diseases. Phenotypic screening is a powerful method in both neglected and non-neglected diseases and has been very successfully used. Identification of molecular targets from phenotypic approaches can be a way to identify potential new drug targets.
引用
收藏
页码:7719 / 7726
页数:8
相关论文
共 50 条
  • [41] Quantum dot approaches for target-based drug screening and multiplexed active biosensing
    Kovtun, Oleg
    Arzeta-Ferrer, Xochitl
    Rosenthal, Sandra J.
    NANOSCALE, 2013, 5 (24) : 12072 - 12081
  • [42] Fragment-Based Phenotypic Lead Discovery To Identify New Drug Seeds That Target Infectious Diseases
    Ayotte, Yann
    Bernet, Eve
    Bilodeau, Francois
    Cimino, Mena
    Gagnon, Dominic
    Lebughe, Marthe
    Mistretta, Maxime
    Ogadinma, Paul
    Ouali, Sarah-Lisa
    Sow, Aissatou Aicha
    Chatel-Chaix, Laurent
    Descoteaux, Albert
    Manina, Giulia
    Richard, Dave
    Veyrier, Frederic
    LaPlante, Steven R.
    ACS CHEMICAL BIOLOGY, 2021, 16 (11) : 2158 - 2163
  • [43] Drug discovery and development for neglected parasitic diseases
    Renslo, Adam R.
    McKerrow, James H.
    NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 701 - 710
  • [44] Phenomic technologies in drug discovery of neglected diseases
    Ulf Nehrbass
    BMC Proceedings, 5 (Suppl 1)
  • [45] In Silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology
    Taboureau, Olivier
    Jorgensen, Flemming Steen
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2011, 14 (05) : 375 - 387
  • [46] Drug discovery and development for neglected parasitic diseases
    Adam R Renslo
    James H McKerrow
    Nature Chemical Biology, 2006, 2 : 701 - 710
  • [47] Introduction: Drug Discovery and Development for Neglected Diseases
    Goupil, Louise S.
    McKerrow, James H.
    CHEMICAL REVIEWS, 2014, 114 (22) : 11131 - 11137
  • [48] A target-based discovery from a parasitic helminth as a novel therapeutic approach for autoimmune diseases
    Ni, Yangyue
    Xiong, Ruiyan
    Zhu, Yuxiao
    Luan, Ning
    Yu, Chuanxin
    Yang, Kun
    Wang, Huiquan
    Xu, Xuejun
    Yang, Yuxuan
    Sun, Siyu
    Shi, Liyun
    Padde, Jon Rob
    Chen, Lin
    Chen, Lu
    Hou, Min
    Xu, Zhipeng
    Lai, Ren
    Ji, Minjun
    EBIOMEDICINE, 2023, 95
  • [49] In silico tools used for compound selection during target-based drug discovery and development
    Caldwell, Gary W.
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (08) : 901 - 923
  • [50] Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery
    Kaminski, Tim
    Gunnarsson, Anders
    Geschwindner, Stefan
    ACS SENSORS, 2017, 2 (01): : 10 - 15